Leading Forward: ASTCT's Vision for 2024-2025

03.26.24

Leading Forward: ASTCT's Vision for 2024-2025

GVHD Insights from Two-time Transplant Recipient, Becky Dame of The Leukemia and Lymphoma Society

02.27.24

GVHD Insights from Two-time Transplant Recipient, Becky Dame of The Leukemia and Lymphoma Society

Adverse Event Reporting to FACT

02.21.24

Adverse Event Reporting to FACT

Using cell-free DNA to detect cGVHD

01.25.24

Using cell-free DNA to detect cGVHD

Titans of Transplant: Dr. Stephanie Lee

01.16.24

Titans of Transplant: Dr. Stephanie Lee

Embarking on a New Year of Collaboration

01.12.24

Embarking on a New Year of Collaboration

Exploring the BMT CTN 1703 Study

12.04.23

Exploring the BMT CTN 1703 Study

Navigating CAR-T Survivorship

11.28.23

Navigating CAR-T Survivorship

Giving Time, Making an Impact

11.21.23

Giving Time, Making an Impact

Fractionated Busulfan preparative regimen for alloHSCT

10.26.23

Fractionated Busulfan preparative regimen for alloHSCT

CD24Fc for GVHD prevention in adults undergoing MUD HSCT

10.12.23

CD24Fc for GVHD prevention in adults undergoing MUD HSCT

Pre-HCT gut microbiota diversity and outcomes in children

10.10.23

Pre-HCT gut microbiota diversity and outcomes in children

MSC effect on thymic regulation to alleviate cGVHD

08.31.23

MSC effect on thymic regulation to alleviate cGVHD

Newborn screening impact on survival after HCT for SCID

08.31.23

Newborn screening impact on survival after HCT for SCID

Exploring de novo late acute GVHD

08.17.23

Exploring de novo late acute GVHD

Axi-cel outcome in treatment for R/R large B-cell lymphoma

08.01.23

Axi-cel outcome in treatment for R/R large B-cell lymphoma

Pharmacy SIG Literature Update: A review of BMT CTN1703

07.28.23

Pharmacy SIG Literature Update: A review of BMT CTN1703

Cyclosporine impact on tolerance induction after allo-HCT

07.27.23

Cyclosporine impact on tolerance induction after allo-HCT

Titans of Transplant: Dr. Rick Jones

07.19.23

Titans of Transplant: Dr. Rick Jones

A Melting Pot of Opportunity

07.12.23

A Melting Pot of Opportunity

Human DPTs directly involved in GVHD pathogenesis

07.06.23

Human DPTs directly involved in GVHD pathogenesis

Impact of cryopreserved grafts on transplant outcomes

06.30.23

Impact of cryopreserved grafts on transplant outcomes

CAST regimen for acute GVHD prophylaxis after HSCT

06.13.23

CAST regimen for acute GVHD prophylaxis after HSCT

Maintenance with ivosidenib post-HCT in IDH1-mutated AML

06.06.23

Maintenance with ivosidenib post-HCT in IDH1-mutated AML

Pharmacy SIG Literature Update: Updated results from TRANSCEND with longer follow- up

06.02.23

Pharmacy SIG Literature Update: Updated results from TRANSCEND with longer follow- up

You Can’t See the Forest for the Trees

05.22.23

You Can’t See the Forest for the Trees

Value of DNA sequencing pre-HCT for AML patients

05.09.23

Value of DNA sequencing pre-HCT for AML patients

Donor lymphocytes engineered with SA-FasL to avoid aGVHD

04.20.23

Donor lymphocytes engineered with SA-FasL to avoid aGVHD

Abatacept for steroid-refractory cGVHD

04.18.23

Abatacept for steroid-refractory cGVHD

Building a Brighter Future for HCT and CT

04.13.23

Building a Brighter Future for HCT and CT

Pharmacy SIG Literature Update: ATG in allogeneic HCT for AML

04.10.23

Pharmacy SIG Literature Update: ATG in allogeneic HCT for AML

Women's History Month Spotlight: Nirali Shah, MD, MHSc

03.30.23

Women's History Month Spotlight: Nirali Shah, MD, MHSc

Women's History Month Spotlight: Betty Ky Hamilton, MD

03.28.23

Women's History Month Spotlight: Betty Ky Hamilton, MD

Women's History Month Spotlight: Nandita Khera, MD, MPH

03.24.23

Women's History Month Spotlight: Nandita Khera, MD, MPH

Women's History Month Spotlight: Alison Gulbis, PharmD, BCOP

03.21.23

Women's History Month Spotlight: Alison Gulbis, PharmD, BCOP

Titans of Transplant: Dr. Micah Skeens

03.15.23

Titans of Transplant: Dr. Micah Skeens

Letermovir prophylaxis against CMV after HCT

03.13.23

Letermovir prophylaxis against CMV after HCT

Viral-Specific T cell use in SCD patients post-HSCT

03.02.23

Viral-Specific T cell use in SCD patients post-HSCT

Treg suppression mechanisms of acute GVHD

02.16.23

Treg suppression mechanisms of acute GVHD

Liso-cel as second-line therapy for large B-cell lymphoma

02.14.23

Liso-cel as second-line therapy for large B-cell lymphoma

Pharmacy SIG Literature Update: PTCy pharmacokinetics and HaploHCT outcomes

02.07.23

Pharmacy SIG Literature Update: PTCy pharmacokinetics and HaploHCT outcomes

Every Step Taken: My Final ASTCT President’s Message

02.02.23

Every Step Taken: My Final ASTCT President’s Message

Shared Minor Histocompatibility Antigens

01.26.23

Shared Minor Histocompatibility Antigens

S100A9 separates GVHD from GVL

01.24.23

S100A9 separates GVHD from GVL

Infusion of Memory T cells after haplo-HSCT

01.19.23

Infusion of Memory T cells after haplo-HSCT

F-652 plus corticosteroids treatment for GI GVHD

01.17.23

F-652 plus corticosteroids treatment for GI GVHD

Pharmacy SIG Literature Update: MMUD with PTCy based GVHD prophylaxis vs. HaploHCT in AM

01.04.23

Pharmacy SIG Literature Update: MMUD with PTCy based GVHD prophylaxis vs. HaploHCT in AM

Update on GVHD Biomarkers

01.03.23

Update on GVHD Biomarkers

Microbiota injury related to Conditioning Regimens

12.22.22

Microbiota injury related to Conditioning Regimens

Impact of pre-HCT therapy on outcome in patients with AML

12.20.22

Impact of pre-HCT therapy on outcome in patients with AML

Impact of HSCT on VOEs requiring medical care SCD patients

12.15.22

Impact of HSCT on VOEs requiring medical care SCD patients

Allo-HCT outcomes in older and medical infirm AML patients

12.13.22

Allo-HCT outcomes in older and medical infirm AML patients

Year-end Evaluation: A “To Do” or an Opportunity?

12.12.22

Year-end Evaluation: A “To Do” or an Opportunity?

CAR-NK activity targets CLL-1 in AML

11.29.22

CAR-NK activity targets CLL-1 in AML

UCART19 for adults with r/r B-ALL

11.24.22

UCART19 for adults with r/r B-ALL

Peripheral T helper cells in chronic GVHD

11.17.22

Peripheral T helper cells in chronic GVHD

Giving Thanks and Giving Back

11.15.22

Giving Thanks and Giving Back

Itacitinib treatment for LR GVHD

11.10.22

Itacitinib treatment for LR GVHD

Pharmacy SIG Literature Update: BuCY versus CY/TBI for Standard Risk B-ALL in CR1 and More

11.09.22

Pharmacy SIG Literature Update: BuCY versus CY/TBI for Standard Risk B-ALL in CR1 and More

Fli-1 Regulates T Cell Immunity in GVHD

11.01.22

Fli-1 Regulates T Cell Immunity in GVHD

TCRvß-CARTs Eliminates Malignant T-cell Clones

10.27.22

TCRvß-CARTs Eliminates Malignant T-cell Clones

Monkeypox in HCT and CAR T

10.26.22

Monkeypox in HCT and CAR T

Late Effects in MCL Patients

10.25.22

Late Effects in MCL Patients

Normalization of Cerebral Hemodynamics Post-HSCT for SCD

10.13.22

Normalization of Cerebral Hemodynamics Post-HSCT for SCD

Pharmacy SIG Literature Update: Pre-transplant Conditioning for AML/MDS with Fludarabine

10.11.22

Pharmacy SIG Literature Update: Pre-transplant Conditioning for AML/MDS with Fludarabine

Immune Cell Profiling in Severe aGVHD

10.11.22

Immune Cell Profiling in Severe aGVHD

Cooling Down or Heating Up

10.10.22

Cooling Down or Heating Up

Biomarkers of Severe CRS and ICANS in B-ALL patients

10.04.22

Biomarkers of Severe CRS and ICANS in B-ALL patients

Immunoregulatory Mechanisms Involving GvL Effect

09.19.22

Immunoregulatory Mechanisms Involving GvL Effect

Allo-HCT for Ph+ ALL Patients in CR1 with CMR

09.15.22

Allo-HCT for Ph+ ALL Patients in CR1 with CMR

TECing a Closer Look at Teclistamab with Dr. Saad Usmani

09.15.22

TECing a Closer Look at Teclistamab with Dr. Saad Usmani

Titans of Transplant: Dr. Rainer Storb

09.13.22

Titans of Transplant: Dr. Rainer Storb

Moonshot: Not Because It’s Easy

09.08.22

Moonshot: Not Because It’s Easy

Pharmacy SIG Literature Update: Impact of Omitting Post-transplant mini-MTX Post alloHCT

09.06.22

Pharmacy SIG Literature Update: Impact of Omitting Post-transplant mini-MTX Post alloHCT

BiTEs Complement CAR T Cell Use in Solid Tumors

08.30.22

BiTEs Complement CAR T Cell Use in Solid Tumors

Serum Proteome Profiling of CRS and ICANS

08.30.22

Serum Proteome Profiling of CRS and ICANS

ImmunoPET Allows Early Detection of Acute GI  GVHD

08.23.22

ImmunoPET Allows Early Detection of Acute GI GVHD

KIR-Favorable Haploidentical HCT in Children

08.18.22

KIR-Favorable Haploidentical HCT in Children

Biomarkers Identify acute GVHD response to Itacitinib

08.16.22

Biomarkers Identify acute GVHD response to Itacitinib

394,044 Steps: Every Step Counts

08.09.22

394,044 Steps: Every Step Counts

The Times They Are A-Changin’

07.12.22

The Times They Are A-Changin’

Titans of Transplant: Dr. Adriana Seber

07.11.22

Titans of Transplant: Dr. Adriana Seber

Phenotypic Escape in CD19 -Directed Therapies

07.05.22

Phenotypic Escape in CD19 -Directed Therapies

Transplant Outcomes in Adults with HLH

06.30.22

Transplant Outcomes in Adults with HLH

Respiratory Viruses in Transplant Candidates

06.28.22

Respiratory Viruses in Transplant Candidates

Donor Plasmacytoid Dendritic Cells Limit GVHD

06.14.22

Donor Plasmacytoid Dendritic Cells Limit GVHD

For Me: Spring has Sprung

06.14.22

For Me: Spring has Sprung

CAR(NAP) T Cells Use in Murine Solid Tumors

05.26.22

CAR(NAP) T Cells Use in Murine Solid Tumors

Zinc Promotes T Cell Reconstitution in Mouse Model of HSCT

05.24.22

Zinc Promotes T Cell Reconstitution in Mouse Model of HSCT

HuCART-19 Plus Ibrutinib Treatment in CLL

05.19.22

HuCART-19 Plus Ibrutinib Treatment in CLL

CAR-NKT cells: More of a Goldilocks or a Kangaroo?

05.02.22

CAR-NKT cells: More of a Goldilocks or a Kangaroo?

HLA-DQ Heterodimers in HCT

04.26.22

HLA-DQ Heterodimers in HCT

I Don’t Know Why We Say Goodbye…

04.12.22

I Don’t Know Why We Say Goodbye…

Naive T-Cell Depletion to Prevent Chronic GVHD

03.29.22

Naive T-Cell Depletion to Prevent Chronic GVHD

Serum Neurofilaments Correlate With ICANS Severity

03.24.22

Serum Neurofilaments Correlate With ICANS Severity

PT-Cy For Prevention of Graft-Versus-Host Disease

03.17.22

PT-Cy For Prevention of Graft-Versus-Host Disease

The Power of Recognition

03.16.22

The Power of Recognition

Manufacturing and Characterization of CMV-CD19 CAR T Cells

03.08.22

Manufacturing and Characterization of CMV-CD19 CAR T Cells

CD45-ADC Mediated Conditioning for Allogeneic HCT

02.22.22

CD45-ADC Mediated Conditioning for Allogeneic HCT

Black History Month Spotlight: Melody Smith, MD, MS

02.21.22

Black History Month Spotlight: Melody Smith, MD, MS

Black History Month Spotlight: Allistair Abraham, MD

02.17.22

Black History Month Spotlight: Allistair Abraham, MD

Black History Month Spotlight: Folashade Otegbeye, MBChB, MPH

02.15.22

Black History Month Spotlight: Folashade Otegbeye, MBChB, MPH

Blinatumomab After Allo-HCT for B-lineage ALL

02.15.22

Blinatumomab After Allo-HCT for B-lineage ALL

We Bend, Not Break

02.14.22

We Bend, Not Break

Tisagenlecleucel Outcomes in R/R Extramedullary ALL

02.03.22

Tisagenlecleucel Outcomes in R/R Extramedullary ALL

Cytogenetics Impact on CAR-T cell Therapy Outcomes

02.01.22

Cytogenetics Impact on CAR-T cell Therapy Outcomes

Pharmacy SIG Literature Update: The Impact of GCSF With Thymoglobulin and More!

01.27.22

Pharmacy SIG Literature Update: The Impact of GCSF With Thymoglobulin and More!

Durable Antitumor Immunity With PRDM1 Knockout

01.25.22

Durable Antitumor Immunity With PRDM1 Knockout

Titans of Transplant: Dr. Mary Horowitz

01.24.22

Titans of Transplant: Dr. Mary Horowitz

Update on GVHD Biomarkers

01.03.22

Update on GVHD Biomarkers

Ofatumumab and Prednisone for Chronic GVHD

12.21.21

Ofatumumab and Prednisone for Chronic GVHD

Reasons to Believe

12.14.21

Reasons to Believe

MSLN Directed CAR T-Cell Therapy in AML

11.30.21

MSLN Directed CAR T-Cell Therapy in AML

FACT Update

11.30.21

FACT Update

Auto-HCT Outcome in Older CR1 AML Patients

11.25.21

Auto-HCT Outcome in Older CR1 AML Patients

Type 1 IFN Feasibility in Peri-HCT Period

11.23.21

Type 1 IFN Feasibility in Peri-HCT Period

Rapamycin Pretreatment of EpCAM CAR-T Cells

11.18.21

Rapamycin Pretreatment of EpCAM CAR-T Cells

Donor Macrophage MHC II Role in CNS cGVHD

11.16.21

Donor Macrophage MHC II Role in CNS cGVHD

FT Regimen for Allo-HCT with MDS

11.09.21

FT Regimen for Allo-HCT with MDS

A Season of Gratitude and Thanks

11.09.21

A Season of Gratitude and Thanks

Biomarker for BOS response after allo-HCT

10.28.21

Biomarker for BOS response after allo-HCT

Impact of TNF and IL-6R on GVHD

10.12.21

Impact of TNF and IL-6R on GVHD

Begin Again

10.12.21

Begin Again

HCT for DLBCL-Richter Transformation

10.07.21

HCT for DLBCL-Richter Transformation

Management of Allo-sensitized HCT Patients

10.05.21

Management of Allo-sensitized HCT Patients

Effects of off-the-shelf allogeneic CAR iNKT

09.30.21

Effects of off-the-shelf allogeneic CAR iNKT

Pretransplant MRD impact for CBF-AML

09.21.21

Pretransplant MRD impact for CBF-AML

CHIP impact on outcome of CAR T-cell therapy

09.09.21

CHIP impact on outcome of CAR T-cell therapy

Common Mission. Shared Purpose.

09.09.21

Common Mission. Shared Purpose.

Pharmacy SIG Literature Update: A Focus on Graft-Versus-Host Disease

08.31.21

Pharmacy SIG Literature Update: A Focus on Graft-Versus-Host Disease

Belumosudil for cGVHD

08.10.21

Belumosudil for cGVHD

When Awards Are More Than Just Awards

08.03.21

When Awards Are More Than Just Awards

Pharmacy SIG Literature Update: Transplantation in Relapsed APL and More!

08.02.21

Pharmacy SIG Literature Update: Transplantation in Relapsed APL and More!

A Deep Dive On Early Time-to-Toci

07.29.21

A Deep Dive On Early Time-to-Toci

Plasma MMP-9 in BOS after allo-HCT

07.29.21

Plasma MMP-9 in BOS after allo-HCT

FACT Update

07.27.21

FACT Update

KTE-X19 in R/R B-cell ALL

07.27.21

KTE-X19 in R/R B-cell ALL

Functions of iNKT cell subsets

07.15.21

Functions of iNKT cell subsets

Outcome of COVID-19 in HCT patients

07.08.21

Outcome of COVID-19 in HCT patients

I’ve Got a Feeling…

07.06.21

I’ve Got a Feeling…

PTCy associated with increased CMV infection

07.06.21

PTCy associated with increased CMV infection

A SWOT Analysis of BiTEs

06.10.21

A SWOT Analysis of BiTEs

Here Comes the Sun (or Science)

06.01.21

Here Comes the Sun (or Science)

FACT Update

05.03.21

FACT Update

In a Time of Change, We’re Driving Change

05.03.21

In a Time of Change, We’re Driving Change

Pharmacy SIG Literature Update: Chemotherapy vs. myeloablative alloHCT in AYA patients

04.26.21

Pharmacy SIG Literature Update: Chemotherapy vs. myeloablative alloHCT in AYA patients

Passing of Dr. Francisco Marty

04.16.21

Passing of Dr. Francisco Marty

Point–Counterpoint: BiTEs vs CAR T-cells

04.12.21

Point–Counterpoint: BiTEs vs CAR T-cells

Achieving More, Together

04.05.21

Achieving More, Together

Deletion of Cbl-b inhibits CAR T-cell exhaustion

03.30.21

Deletion of Cbl-b inhibits CAR T-cell exhaustion

Telomere length association with NRM in MDS post-SCT

03.30.21

Telomere length association with NRM in MDS post-SCT

A Deep Dive on Chronic GVHD

03.24.21

A Deep Dive on Chronic GVHD

Women's History Month Spotlight: Laura Whited, PharmD, BCOP

03.23.21

Women's History Month Spotlight: Laura Whited, PharmD, BCOP

Sitagliptin prevention of aGVHD

03.23.21

Sitagliptin prevention of aGVHD

Women's History Month Spotlight: Stefanie Sarantopoulos, M.D., Ph.D.

03.19.21

Women's History Month Spotlight: Stefanie Sarantopoulos, M.D., Ph.D.

Auto vs. Allo HCT for poor-risk peripheral T-NHL

03.19.21

Auto vs. Allo HCT for poor-risk peripheral T-NHL

Women's History Month Spotlight: Dianna Sue Howard, M.D.

03.18.21

Women's History Month Spotlight: Dianna Sue Howard, M.D.

Reflections On a New (Leadership) Year

03.02.21

Reflections On a New (Leadership) Year

What a Difference a Year Makes

02.03.21

What a Difference a Year Makes

#TCTM21: A Virtual Meeting with Real-Life Tweeting

01.14.21

#TCTM21: A Virtual Meeting with Real-Life Tweeting

Join Us at the TCT Meetings of ASTCT and CIBMTR This Year

01.11.21

Join Us at the TCT Meetings of ASTCT and CIBMTR This Year

In a Year Fraught with Challenges, Remember Our Strengths

12.08.20

In a Year Fraught with Challenges, Remember Our Strengths

Looking for a Way to Give Back this Holiday Season? Consider ASTCT

11.02.20

Looking for a Way to Give Back this Holiday Season? Consider ASTCT

Wherever We Meet, We Will Learn Together

10.14.20

Wherever We Meet, We Will Learn Together

Never Too Old to Learn

09.11.20

Never Too Old to Learn

Leadership Means Being Part of the Solution

08.06.20

Leadership Means Being Part of the Solution

Defining the Role of Blinatumomab in Pediatric ALL

07.28.20

Defining the Role of Blinatumomab in Pediatric ALL

MRD Monitoring “Essential” in CML

07.20.20

MRD Monitoring “Essential” in CML

Transfusion Updates for the Pandemic Era

07.17.20

Transfusion Updates for the Pandemic Era

MRD “Meets Criteria for Broad Clinical Use”

07.13.20

MRD “Meets Criteria for Broad Clinical Use”

NGS-MRD Assay Shows Promise in Real-World Analysis

06.12.20

NGS-MRD Assay Shows Promise in Real-World Analysis

Joint Statement from ASTCT, CIBMTR, FACT, ISCT and EBMT

06.08.20

Joint Statement from ASTCT, CIBMTR, FACT, ISCT and EBMT

Racism Has No Place Here – And We Need to Be the Change

06.03.20

Racism Has No Place Here – And We Need to Be the Change

Policy Perspectives: Coronavirus Update

06.02.20

Policy Perspectives: Coronavirus Update

Talking to your Patients About MRD

05.27.20

Talking to your Patients About MRD

COVID-19 & Leadership

04.21.20

COVID-19 & Leadership

BiTE Therapy in Multiple Myeloma

04.13.20

BiTE Therapy in Multiple Myeloma

ASTCT Continues to Support You Through COVID-19

04.07.20

ASTCT Continues to Support You Through COVID-19

Updates on COVID-19 from the ASTCT President

03.23.20

Updates on COVID-19 from the ASTCT President

A Message from ASTCT President Pavan Reddy on COVID-19

03.17.20

A Message from ASTCT President Pavan Reddy on COVID-19

Coronavirus Funding Legislation

03.17.20

Coronavirus Funding Legislation

FACT Update: Join Us at the 2020 TCT Meetings

01.20.20

FACT Update: Join Us at the 2020 TCT Meetings

The Role of MRD in Multiple Myeloma

01.10.20

The Role of MRD in Multiple Myeloma

Looking Ahead to the New Year and New Opportunities

01.10.20

Looking Ahead to the New Year and New Opportunities

As 2019 Ends, Let's Reflect On Another Great Year

12.04.19

As 2019 Ends, Let's Reflect On Another Great Year

ASTCT Creates Powerful Possibilities -- Both Personally and Professionally

11.04.19

ASTCT Creates Powerful Possibilities -- Both Personally and Professionally

ASTCT Pharmacy SIG Summer 2019 Newsletter

09.20.19

ASTCT Pharmacy SIG Summer 2019 Newsletter

As the Colors Change, So Do We at ASTCT

09.05.19

As the Colors Change, So Do We at ASTCT

As Summer Begins to Sunset, Students and Standards Continue to Inspire

08.02.19

As Summer Begins to Sunset, Students and Standards Continue to Inspire

Amazing Education and Fellowship: A Perspective from CRTC

07.29.19

Amazing Education and Fellowship: A Perspective from CRTC

Reflecting On a Life-Altering Diagnosis: One BMT Professional’s Journey

07.19.19

Reflecting On a Life-Altering Diagnosis: One BMT Professional’s Journey

Thank You Dr. Miguel Perales

07.02.19

Thank You Dr. Miguel Perales

Teamwork Makes the Dream Work: Coming Together Makes Us Stronger

06.04.19

Teamwork Makes the Dream Work: Coming Together Makes Us Stronger

Search